Product Description
an antineoplastic antibiotic that binds to DNA causing strand scissions (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15357628/)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, Denmark, France, Hungary, Italy, Norway, Poland, Spain
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hodgkin Lymphoma
Phase 2: Esophageal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-000086-74 |
2017-000086-74 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2024-11-12 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-506419-16-00 |
C25003 | P3 |
Active, not recruiting |
Hodgkin Lymphoma |
2026-01-20 |
2025-05-02 |
Treatments |
|
2020-002878-27 |
2020-002878-27 | P2 |
Active, not recruiting |
Esophageal Cancer |
None |
2022-03-13 |
Treatments |